Pharmaceutical measures to prevent doxorubicin-induced cardiotoxicity

Mini-Reviews in Medicinal Chemistry

Volumn 17, Issue 1, 2017, Pages 44-50

  Liu, Hao ^a,b   Wang, Haiyan ^a   Xiang, Dingcheng ^c   Guo, Wangang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

Author keywords

Cardiotoxicity; Doxorubicin; RNA binding protein quaking; Statins

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA; DOXORUBICIN; ENALAPRIL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPIRUBICIN; FELODIPINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRON; LIPOSOME; MITOXANTRONE; NEBIVOLOL; NITRIC OXIDE; OLMESARTAN; PLACEBO; POLYMER; POLYOXALATE VANILLYL ALCOHOL; RAZOXANE; RNA BINDING PROTEIN; RNA BINDING PROTEIN QKI; ROSUVASTATIN; UBIQUINONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; ANTINEOPLASTIC ANTIBIOTIC; CARDIOTONIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOID LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; AUTOPHAGY; BREAST CANCER; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DNA DAMAGE; DRUG APPROVAL; DRUG CYTOTOXICITY; DRUG DOSAGE FORM COMPARISON; DRUG MECHANISM; DRUG RESEARCH; ENZYME PHOSPHORYLATION; EWING SARCOMA; GLIOBLASTOMA; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HUMAN; IRON CHELATION; LEUKEMIA; LYMPHOMA; METASTASIS; MYELODYSPLASTIC SYNDROME; MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; REVIEW; SMALL CELL LUNG CANCER; SOFT TISSUE SARCOMA; NEOPLASMS;

ANTIBIOTICS, ANTINEOPLASTIC; CARDIOTONIC AGENTS; CARDIOTOXICITY; DOXORUBICIN; HUMANS; NEOPLASMS;

EID: 85016390531     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557516666160621083659     Document Type: Review

References (70)

1. Siegel, R. L.; Miller, K.D.; Jemal, A. Cancer statistics, 2015. CA Cancer J. Clin., 2015, 65(1), 5-29.
2. Oeffinger, K.C.; Mertens, A.C.; Sklar, C.A.; Kawashima, T.; Hudson, M.M.; Meadows, A.T.; Friedman, D.L.; Marina, N.; Hobbie, W.; Kadan-Lottick, N.S.; Schwartz, C.L.; Leisenring, W.; Robison, L.L. Chronic health conditions in adult survivors of childhood cancer. N. Engl. J. Med., 2006, 355(15), 1572-1582.
3. Carvalho, C.; Santos, R. X.; Cardoso, S.; Correia, S.; Oliveira, P.J.; Santos, M.S.; Moreira, P.I. Doxorubicin: the good, the bad and the ugly effect. Curr. Med. Chem., 2009, 16(25), 3267-3285.
4. Smith, L.A.; Cornelius, V.R.; Plummer, C.J.; Levitt, G.; Verrill, M.; Canney, P.; Jones, A. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer, 2010, 10, 337.
5. Kremer, L.C.; van Dalen E.C.; Offringa, M.; Voute, P.A. Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann. Oncol.: official J. Euro. Soc. Med. Oncol. ESMO, 2002, 13(4), 503-512.
6. Chao, H.H.; Liu, J.C.; Hong, H.J.; Lin, J.W.; Chen, C.H.; Cheng, T.H. L-carnitine reduces doxorubicin-induced apoptosis through a prostacyclin-mediated pathway in neonatal rat cardiomyocytes. Int. J. Cardiol., 2011, 146(2), 145-152.
7. Lawton, P.A.; Spittle, M.F.; Ostrowski, M.J.; Young, T.; Madden, F.; Folkes, A.; Hill, B.T.; MacRae, K. A comparison of doxorubicin, epirubicin and mitozantrone as single agents in advanced breast carcinoma. Clin. Oncol. (Royal College of Radiologists (Great Britain)), 1993, 5(2), 80-84.
8. Bontenbal, M.; Andersson, M.; Wildiers, J.; Cocconi, G.; Jassem, J.; Paridaens, R.; Rotmensz, N.; Sylvester, R.; Mouridsen, H.T.; Klijn, J.G.; van Oosterom AT. Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group. Br. J. Cancer, 1998, 77(12), 2257-2263.
9. Homesley, H.D.; Harry, D.S.; O'Toole, R.V.; Hoogstraten, B.; Franklin, E.W.; Cavanagh, D.; Nahhas, W.A.; Smith, J.J.; Lovelace, J.V. Randomized comparison of cisplatin plus epirubicin or doxorubicin for advanced epithelial ovarian carcinoma. A multicenter trial. Am. J. Clin. Oncol., 1992, 15(2), 129-134.
10. Lahtinen, R.; Kuikka, J.; Nousiainen, T.; Uusitupa, M.; Lansimies, E. Cardiotoxicity of epirubicin and doxorubicin: a double-blind randomized study. Eur. J. Haematol., 1991, 46(5), 301-305.
11. van Dalen E.C.; Michiels, E.M.; Caron, H.N.; Kremer, L.C. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Sys. Rev., 2010, 5, CD005006.
12. Gabizon, A. A. Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin. Cancer Res., 2001, 7(2), 223-225.
13. Heintel, D.; Skrabs, C.; Hauswirth, A.; Eigenberger, K.; Einberger, C.; Raderer, M.; Sperr, W.R.; Knobl, P.; Mullauer, L.; Uffmann, M.; Dieckmann, K.; Gaiger, A.; Jager, U. Nonpegylated liposomal doxorubicin is highly active in patients with B and T/NK cell lymphomas with cardiac comorbidity or higher age. Ann. Hematol., 2010, 89(2), 163-169.
14. Lipshultz, S.E.; Scully, R.E.; Lipsitz, S.R.; Sallan, S.E.; Silverman, L.B.; Miller, T.L.; Barry, E.V.; Asselin, B.L.; Athale, U.; Clavell, L.A.; Larsen, E.; Moghrabi, A.; Samson, Y.; Michon, B.; Schorin, M.A.; Cohen, H.J.; Neuberg, D.S.; Orav, E.J.; Colan, S.D. Assessment of dexrazoxane as a cardioprotectant in doxorubicintreated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol., 2010, 11(10), 950-961.
15. Marty, M.; Espie, M.; Llombart, A.; Monnier, A.; Rapoport, B.L.; Stahalova, V. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann. Oncol.: official J. Euro. Soc. Med. Oncol. ESMO, 2006, 17(4), 614-622.
16. Sterba, M.; Popelova, O.; Vavrova, A.; Jirkovsky, E.; Kovarikova, P.; Gersl, V.; Simunek, T. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxid. Redox Signal., 2013, 18(8), 899-929.
17. Zhou, L.; Sung, R.Y.; Li, K.; Pong, N.H.; Xiang, P.; Shen, J.; Ng, P.C.; Chen, Y. Cardioprotective effect of dexrazoxane in a rat model of myocardial infarction: anti-apoptosis and promoting angiogenesis. Int. J. Cardiol., 2011, 152(2), 196-201.
18. Swain, S.M.; Whaley, F.S.; Gerber, M.C.; Weisberg, S.; York, M.; Spicer, D.; Jones, S.E.; Wadler, S.; Desai, A.; Vogel, C.; Speyer, J.; Mittelman, A.; Reddy, S.; Pendergrass, K.; Velez-Garcia, E.; Ewer, M.S.; Bianchine, J.R.; Gams, R.A. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J. Clin. Oncol., 1997, 15(4), 1318-1332.
19. Hensley, M. L.; Hagerty, K.L.; Kewalramani, T.; Green, D.M.; Meropol, N.J.; Wasserman, T.H.; Cohen, G.I.; Emami, B.; Gradishar, W.J.; Mitchell, R.B.; Thigpen, J.T.; Trotti, A. 3rd, von, H.D., Schuchter, L.M. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J. Clin. Oncol., 2009, 27(1), 127-145.
20. Lopez, M.; Vici, P.; Di, L. K.; Conti, F.; Paoletti, G.; Ferraironi, A.; Sciuto, R.; Giannarelli, D.; Maini, C. L. Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J. Clin. Oncol., 1998, 16(1), 86-92.
21. van Dalen E.C.; Caron, H. N.; Dickinson, H. O.; Kremer, L. C. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Sys. Rev., 2011, (6), CD003917.
22. Wexler, L. H.; Andrich, M. P.; Venzon, D.; Berg, S. L.; Weaver-McClure, L.; Chen, C. C.; Dilsizian, V.; Avila, N.; Jarosinski, P.; Balis, F. M.; Poplack, D. G.; Horowitz, M. E. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J. Clin. Oncol., 1996, 14(2), 362-372.
23. Lipshultz, S. E.; Rifai, N.; Dalton, V. M.; Levy, D. E.; Silverman, L. B.; Lipsitz, S. R.; Colan, S. D.; Asselin, B. L.; Barr, R. D.; Clavell, L. A.; Hurwitz, C. A.; Moghrabi, A.; Samson, Y.; Schorin, M. A.; Gelber, R. D.; Sallan, S. E. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N. Engl. J. Med., 2004, 351(2), 145-153.
24. Choi, H.S., Park, E.S., Kang, H.J., Shin, H.Y., Noh, C.I., Yun, Y.S., Ahn, H.S., Choi, J.Y. Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors. J. Kor. Med. Sci., 2010, 25(9), 1336-1342.
25. Walker, D.M.; Fisher, B.T.; Seif, A.E.; Huang, Y. S.; Torp, K.; Li, Y.; Aplenc, R. Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: analysis of a national cohort of patients in the Pediatric Health Information Systems database. Pediatr. Blood Cancer, 2013, 60(4), 616-620.
26. Tebbi, C.K.; London, W.B.; Friedman, D.; Villaluna, D.; De Alarcon P.A.; Constine, L.S.; Mendenhall, N.P.; Sposto, R.; Chauvenet, A.; Schwartz, C.L. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J. Clin. Oncol., 2007, 25(5), 493-500.
27. Salzer, W. L.; Devidas, M.; Carroll, W. L.; Winick, N.; Pullen, J.; Hunger, S. P.; Camitta, B. A. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group. Leukemia, 2010, 24(2), 355-370.
28. Seif, A. E.; Walker, D. M.; Li, Y.; Huang, Y. S.; Kavcic, M.; Torp, K.; Bagatell, R.; Fisher, B. T.; Aplenc, R. Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients. Pediatr. Blood Cancer, 2014.
29. Sharma, H.; Pathan, R. A.; Kumar, V.; Javed, S.; Bhandari, U. Anti-apoptotic potential of rosuvastatin pretreatment in murine model of cardiomyopathy. Int. J. Cardiol., 2011, 150(2), 193-200.
30. Ramanjaneyulu, S. V.; Trivedi, P. P.; Kushwaha, S.; Vikram, A.; Jena, G. B. Protective role of atorvastatin against doxorubicininduced cardiotoxicity and testicular toxicity in mice. J. Physiol. Biochem., 2013, 69(3), 513-525.
31. Huang, C.; Zhang, X.; Ramil, J. M.; Rikka, S.; Kim, L.; Lee, Y.; Gude, N. A.; Thistlethwaite, P. A.; Sussman, M. A.; Gottlieb, R. A., Gustafsson, A. B. Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice. Circulation, 2010, 121(5), 675-683.
32. Yoshida, M.; Shiojima, I.; Ikeda, H.; Komuro, I. Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATM-p53-apoptosis pathway and attenuated by pitavastatin through the inhibition of Rac1 activity. J. Mol. Cell Cardiol., 2009, 47(5), 698-705.
33. Seicean, S.; Seicean, A.; Plana, J. C.; Budd, G. T.; Marwick, T. H. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J. Am. Coll. Cardiol., 2012, 60(23), 2384-2390.
34. Acar, Z.; Kale, A.; Turgut, M.; Demircan, S.; Durna, K.; Demir, S.; Meric, M.; Agac, M. T. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J. Am. Coll. Cardiol., 2011, 58(9), 988-989.
35. Conklin, K. A. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr. Cancer Ther., 2004, 3(4), 294-300.
36. Pepe, S.; Marasco, S. F.; Haas, S. J.; Sheeran, F. L.; Krum, H.; Rosenfeldt, F. L. Coenzyme Q10 in cardiovascular disease. Mitochondrion, 2007, 7 Suppl, S154-167.
37. El-Sheikh, A. A.; Morsy, M. A.; Mahmoud, M. M.; Rifaai, R. A.; Abdelrahman, A. M. Effect of coenzyme-q10 on Doxorubicin induced nephrotoxicity in rats. Adv. Pharmacol. Sci., 2012, 2012, 981461.
38. El-Sheikh, A. A.; Morsy, M. A.; Mahmoud, M. M.; Rifaai, R. A. Protective mechanisms of coenzyme-Q10 may involve upregulation of testicular P-glycoprotein in doxorubicin-induced toxicity. Environ. Toxicol. Pharmacol., 2014, 37(2), 772-781.
39. Chandran, K.; Aggarwal, D.; Migrino, R. Q.; Joseph, J.; McAllister, D.; Konorev, E. A.; Antholine, W. E.; Zielonka, J.; Srinivasan, S.; Avadhani, N. G.; Kalyanaraman, B. Doxorubicin inactivates myocardial cytochrome c oxidase in rats: cardioprotection by Mito-Q. Biophys. J., 2009, 96(4), 1388-1398.
40. Iarussi, D.; Auricchio, U.; Agretto, A.; Murano, A.; Giuliano, M.; Casale, F.; Indolfi, P.; Iacono, A. Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Mol. Aspects Med., 1994, 15 Suppl, s207-212.
41. Kalay, N.; Basar, E.; Ozdogru, I.; Er, O.; Cetinkaya, Y.; Dogan, A.; Inanc, T.; Oguzhan, A.; Eryol, N. K.; Topsakal, R.; Ergin, A. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J. Am. Coll. Cardiol., 2006, 48(11), 2258-2262.
42. de Nigris F.; Rienzo, M.; Schiano, C.; Fiorito, C.; Casamassimi, A.; Napoli, C. Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart. Euro. J. cancer (Oxford, England: 1990), 2008, 44(3), 334-340.
43. Maffei, A.; Di, P. A.; Carangi, R.; Carullo, P.; Poulet, R.; Gentile, M. T.; Vecchione, C.; Lembo, G. Nebivolol induces nitric oxide release in the heart through inducible nitric oxide synthase activation. Hypertension, 2007, 50(4), 652-656.
44. Blaes, A. H.; Gaillard, P.; Peterson, B. A.; Yee, D.; Virnig, B. Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy. Breast Cancer Res. Treat., 2010, 122(2), 585-590.
45. Cardinale, D.; Colombo, A.; Sandri, M. T.; Lamantia, G.; Colombo, N.; Civelli, M.; Martinelli, G.; Veglia, F.; Fiorentini, C.; Cipolla, C. M. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation, 2006, 114(23), 2474-2481.
46. Lipshultz, S. E.; Lipsitz, S. R.; Sallan, S. E.; Simbre, V. C. 2nd; Shaikh, S. L.; Mone, S. M.; Gelber, R. D.; Colan, S. D. Long-term enalapril therapy for left ventricular dysfunction in doxorubicintreated survivors of childhood cancer. J. Clin. Oncol., 2002, 20(23), 4517-4522.
47. Toko, H.; Oka, T.; Zou, Y.; Sakamoto, M.; Mizukami, M.; Sano, M.; Yamamoto, R.; Sugaya, T.; Komuro, I. Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy. Hypertens. Res., 2002, 25(4), 597-603.
48. Iqbal, M.; Dubey, K.; Anwer, T.; Ashish, A.; Pillai, K. K. Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats. Pharmacol. Rep., 2008, 60(3), 382-390.
49. Ibrahim, M. A.; Ashour, O. M.; Ibrahim, Y. F.; El-Bitar, H. I.; Gomaa, W.; Abdel-Rahim, S. R. Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacol. Res., 2009, 60(5), 373-381.
50. Nakamae, H.; Tsumura, K.; Terada, Y.; Nakane, T.; Nakamae, M.; Ohta, K.; Yamane, T.; Hino, M. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer, 2005, 104(11), 2492-2498.
51. Sugawara, H.; Tobise, K.; Kikuchi, K. Antioxidant effects of calcium antagonists on rat myocardial membrane lipid peroxidation. Hypertens. Res., 1996, 19(4), 223-228.
52. Gandhi, H.; Patel, V. B.; Mistry, N.; Patni, N.; Nandania, J.; Balaraman, R. Doxorubicin mediated cardiotoxicity in rats: protective role of felodipine on cardiac indices. Environ. Toxicol. Pharmacol., 2013, 36(3), 787-795.
53. 2-responsive molecularly engineered polymer nanoparticles as ischemia/reperfusion-targeted nanotherapeutic agents. Sci. Rep., 2013, 3, 2233.
54. 2-responsive anti-oxidant polymer nanoparticles for doxorubicin-induced cardiomyopathy. Biomaterials, 2014, 35(22), 5944-5953.
55. Simunek, T.; Sterba, M.; Popelova, O.; Adamcova, M.; Hrdina, R.; Gersl, V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol. Rep., 2009, 61(1), 154-171.
56. Granados-Principal, S.; Quiles, J.L.; Ramirez-Tortosa, C.L.; Sanchez-Rovira, P.; Ramirez-Tortosa, M.C. New advances in molecular mechanisms and the prevention of adriamycin toxicity by antioxidant nutrients. Food Chem. Toxicol., 2010, 48(6), 1425-1438.
57. Galarneau, A.; Richard, S. The STAR RNA binding proteins GLD-1, QKI, SAM68 and SLM-2 bind bipartite RNA motifs. BMC Mol. Biol., 2009, 10, 47.
58. Guo, W.; Shi, X.; Liu, A.; Yang, G.; Yu, F.; Zheng, Q.; Wang, Z.; Allen, D. G.; Lu, Z. RNA binding protein QKI inhibits the ischemia/reperfusion-induced apoptosis in neonatal cardiomyocytes. Cell. Physiol. Biochem., 2011, 28(4), 593-602.
59. Guo, W.; Jiang, T.; Lian, C.; Wang, H.; Zheng, Q.; Ma, H. QKI deficiency promotes FoxO1 mediated nitrosative stress and endoplasmic reticulum stress contributing to increased vulnerability to ischemic injury in diabetic heart. J. Mol. Cell. Cardiol., 2014, 75, 131-140.
60. Fu, X.; Feng, Y. QKI-5 suppresses cyclin D1 expression and proliferation of oral squamous cell carcinoma cells via MAPK signalling pathway. Intl. J. Oral. Maxillofac Surg., 2014.
61. Lu, W.; Feng, F.; Xu, J.; Lu, X.; Wang, S.; Wang, L.; Lu, H.; Wei, M.; Yang, G.; Wang, L.; Lu, Z.; Liu, Y.; Lei, X. QKI impairs selfrenewal and tumorigenicity of oral cancer cells via repression of SOX2. Cancer Biol. Ther., 2014, 15(9), 1174-1184.
62. Zong, F. Y.; Fu, X.; Wei, W. J.; Luo, Y. G.; Heiner, M.; Cao, L. J.; Fang, Z.; Fang, R.; Lu, D.; Ji, H.; Hui, J. The RNA-binding protein QKI suppresses cancer-associated aberrant splicing. PLoS Genet., 2014, 10(4), e1004289.
63. Zhao, Y.; Zhang, G.; Wei, M.; Lu, X.; Fu, H.; Feng, F.; Wang, S.; Lu, W.; Wu, N.; Lu, Z.; Yuan, J. The tumor suppressing effects of QKI-5 in prostate cancer: a novel diagnostic and prognostic protein. Cancer Biol. Ther., 2014, 15(1), 108-118.
64. Chen, A.J.; Paik, J.H.; Zhang, H.; Shukla, S. A.; Mortensen, R.; Hu, J.; Ying, H.; Hu, B.; Hurt, J.; Farny, N.; Dong, C.; Xiao, Y.; Wang, Y. A.; Silver, P. A.; Chin, L.; Vasudevan, S.; Depinho, R. A. STAR RNA-binding protein Quaking suppresses cancer via stabilization of specific miRNA. Genes. Dev., 2012, 26(13), 1459-1472.
65. Yang, G.; Fu, H.; Zhang, J.; Lu, X.; Yu, F.; Jin, L.; Bai, L.; Huang, B.; Shen, L.; Feng, Y.; Yao, L.; Lu, Z. RNA-binding protein quaking, a critical regulator of colon epithelial differentiation and a suppressor of colon cancer. Gastroenterology, 2010, 138(1), 231-240.e1-5.
66. Newman, T. B.; Hulley, S. B. Carcinogenicity of lipid-lowering drugs. JAMA, 1996, 275(1), 55-60.
67. Shepherd, J.; Blauw, G. J.; Murphy, M. B.; Bollen, E. L.; Buckley, B.M.; Cobbe, S. M.; Ford, I.; Gaw, A.; Hyland, M.; Jukema, J. W.; Kamper, A. M.; Macfarlane, P. W.; Meinders, A. E.; Norrie, J.; Packard, C. J.; Perry, I. J.; Stott, D.J.; Sweeney, B. J.; Twomey, C.; Westendorp, R. G. PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002, 23, 360(9346), 1623-30.
68. Chan, K.K.; Oza, A.M.; Siu, L.L. The statins as anticancer agents. Clin. Cancer Res., 2003, 9(1), 10-19.
69. Denoyelle, C.; Vasse, M.; Korner, M.; Mishal, Z.; Ganne, F.; Vannier, J. P.; Soria, J.; Soria, C. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis, 2001, 22(8), 1139-1148.
70. Jiang, P.; Mukthavaram, R.; Chao, Y.; Nomura, N.; Bharati, I. S.; Fogal, V.; Pastorino, S.; Teng, D.; Cong, X.; Pingle, S. C.; Kapoor, S.; Shetty, K.; Aggrawal, A.; Vali, S.; Abbasi, T.; Chien, S.; Kesari, S. In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells. Br. J. Cancer, 2014, 111(8), 1562-1571.